Physician profile
Keith A Waguespack
NPI 1124014659
$28,562.01
in general payments reported to CMS, 2019-2025
37 companies · $962 in 2025
The $962 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,519 · 2020: $1,988 · 2021: $17K · 2022: $5,595 · 2023: $477 · 2024: $608 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,933 · Grant: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,932.51 |
| Grant | $113.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $20,645.40 | 2021-2024 | |
| Neotract INC. | $2,012.74 | 2019-2020 | |
| Astellas Pharma US INC | $1,038.33 | 2019-2025 | Myrbetriq, Xtandi |
| Boston Scientific Corporation | $677.86 | 2019-2025 | Spaceoar Vue System - 10ml, Lithovue, General - Therapies |
| Janssen Biotech, INC. | $653.05 | 2019-2025 | Erleada, Akeega |
| Abbvie INC. | $508.96 | 2019-2024 | Lupron Depot |
| Pfizer INC. | $285.22 | 2019-2025 | |
| Olympus America INC. | $231.89 | 2019-2025 | Itind System |
| Blue Earth Diagnostics | $224.71 | 2019-2025 | Posluma |
| Myovant Sciences INC. | $211.77 | 2021-2022 | |
| Urogen Pharma, INC. | $211.56 | 2020-2025 | Jelmyto |
| Axonics, INC. | $177.85 | 2022-2024 | Bulkamid |
| Sumitomo Pharma America, INC. | $176.36 | 2023-2025 | Orgovyx, Gemtesa |
| Tolmar Pharmaceuticals, INC. | $171.64 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $146.69 | 2019-2025 | Adstiladrin |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $129.45 | 2020-2021 | |
| Dendreon Pharmaceuticals LLC | $120.81 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $118.02 | 2019-2025 | |
| Intuitive Surgical, INC. | $113.16 | 2025 | |
| Merck Sharp & Dohme LLC | $99.55 | 2021-2024 | Keytruda, Welireg |
| Urovant Sciences INC | $88.95 | 2021-2022 | |
| Accord Healthcare, INC. | $76.17 | 2022-2025 | |
| Travere Therapeutics, INC. | $64.45 | 2019-2020 | |
| Laborie Medical Technologies Corp. | $61.52 | 2022-2025 | |
| Endo Pharmaceuticals INC. | $47.40 | 2021 | |
| Myriad Genetic Laboratories, INC. | $43.30 | 2021-2025 | Myrisk |
| Biotissue Holdings INC. | $35.73 | 2022 | |
| Mission Pharmacal Company | $27.54 | 2019 | |
| Palette Life Sciences, INC. | $26.66 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.33 | 2024 | |
| Novartis Pharmaceuticals Corporation | $23.41 | 2022 | |
| Amgen INC. | $19.16 | 2021 | |
| Menarini Silicon Biosystems, INC. | $18.67 | 2023 | Cellsearch |
| Kowa Pharmaceuticals America, INC. | $15.60 | 2023 | Seglentis |
| Tolmar, INC. | $13.31 | 2023 | |
| Medtronic USA, INC. | $12.25 | 2020 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Waguespack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.